Search Results - "Shimazaki, Ryutaro"

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study by Akizawa, Tadao, Shimazaki, Ryutaro, Fukagawa, Masafumi

“…Evocalcet has been developed as a new calcimimetic agent for hemodialysis (HD) patients with secondary hyperparathyroidism (HDSHPT), eliciting fewer…”
Get full text

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy by Kosaka, Yoshimasa, Rai, Yoshiaki, Masuda, Norikazu, Takano, Toshimi, Saeki, Toshiaki, Nakamura, Seigo, Shimazaki, Ryutaro, Ito, Yoshinori, Tokuda, Yutaka, Tamura, Kazuo

“…Purpose Pegfilgrastim is a pegylated form of filgrastim, a recombinant protein of granulocyte colony-stimulating factor, that is used to reduce the risk of…”
Get full text

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients by Shigematsu, Takashi, Shimazaki, Ryutaro, Fukagawa, Masafumi, Akizawa, Tadao

“…Background This study investigated the pharmacokinetics, pharmacodynamics, and safety of multiple doses of evocalcet in Japanese secondary hyperparathyroidism…”
Get full text

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study by Akizawa, Tadao, Shimazaki, Ryutaro, Shiramoto, Masanari, Fukagawa, Masafumi

“…Background and Objectives Evocalcet is a novel calcimimetic agent with potential to improve the treatment of secondary hyperparathyroidism in patients with…”
Get full text

A randomized, double‐blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma by Kubo, Kohmei, Miyazaki, Yasuhiko, Murayama, Tohru, Shimazaki, Ryutaro, Usui, Noriko, Urabe, Akio, Hotta, Tomomitsu, Tamura, Kazuo

“…Summary Pegfilgrastim is a pegylated form of the granulocyte‐colony stimulating factor, filgrastim. Herein, we report the results of a multicentre, randomized,…”
Get full text

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis by Yokoyama, Keitaro, Shimazaki, Ryutaro, Fukagawa, Masafumi, Akizawa, Tadao

“…Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), and as the disease progresses SHPT is associated with systemic…”
Get full text

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial by Masuda, Norikazu, Tokuda, Yutaka, Nakamura, Seigo, Shimazaki, Ryutaro, Ito, Yoshinori, Tamura, Kazuo

“…Purpose A phase II, open-label, dose-finding, randomized study was performed to evaluate the recommended dose of pegfilgrastim in Japanese breast cancer…”
Get full text

High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment by Tsubakihara, Yoshiharu, Akizawa, Tadao, Iwasaki, Manabu, Shimazaki, Ryutaro

“…Our goal was to investigate the effect modification of maintaining a high Hb target range through erythropoiesis‐stimulating agent therapy on the renal outcome…”
Get full text

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients by Tsuruya, Kazuhiko, Shimazaki, Ryutaro, Fukagawa, Masafumi, Akizawa, Tadao

“…Background Secondary hyperparathyroidism (SHPT) is a serious and common complication in patients receiving peritoneal dialysis (PD). Cinacalcet is currently…”
Get full text

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan by Shigematsu, Takashi, Shimazaki, Ryutaro, Fukagawa, Masafumi, Akizawa, Tadao

“…Cinacalcet is a positive allosteric modulator of calcium-sensing receptors in the parathyroid gland and an effective treatment for secondary…”
Get full text

Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans by Narushima, Kazuya, Maeda, Hiroshi, Shiramoto, Masanari, Endo, Yuichi, Ohtsuka, Satoko, Nakamura, Hiroaki, Nagata, Yoshinori, Uchimura, Tatsuo, Kannami, Ayako, Shimazaki, Ryutaro, Fukagawa, Masafumi, Akizawa, Tadao

“…Evocalcet is a novel calcimimetic agent for the treatment of secondary hyperparathyroidism (SHPT). This study evaluated the effects of evocalcet on inhibition…”
Get full text

An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome by Endo, Shigeatsu, Shimazaki, Ryutaro

“…A recombinant form of antithrombin (AT), called AT gamma, is being developed as an alternative to AT derived from human plasma. To compare the efficacy and…”
Get full text

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes by Jang, Jun Ho, Harada, Hironori, Shibayama, Hirohiko, Shimazaki, Ryutaro, Kim, Hyeoung-Joon, Sawada, Kenichi, Mitani, Kinuko

“…Darbepoetin alfa (DA) is a standard treatment for anemia in lower-risk MDS. However, to date there has been no comparative study to investigate the initial…”
Get full text

Nrf2 activator for the treatment of kidney diseases by Yamawaki, Kengo, Kanda, Hironori, Shimazaki, Ryutaro

“…Kidney diseases are highly prevalent worldwide, and significantly reduce the quality of life of patients, creating an urgent need for effective therapeutic…”
Get full text

Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate by Matsushita, Kunihiro, Chen, Jingsha, Sang, Yingying, Ballew, Shoshana H, Shimazaki, Ryutaro, Fukagawa, Masafumi, Imai, Enyu, Coresh, Josef, Hishida, Akira

“…Predominantly based on North American and European studies, 30% to 40% declines in estimated glomerular filtration rate (eGFR) over a few years are strongly…”
Get more information

Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension by Kadowaki, Takashi, Muto, Satsuki, Ouchi, Yoshiumi, Shimazaki, Ryutaro, Seino, Yutaka

“…We examined the efficacy and safety of saxagliptin as an add-on to insulin in Japanese patients with type 2 diabetes mellitus. We randomized 240 patients with…”
Get more information

Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism by Takeuchi, Yasuhiro, Takahashi, Shunsuke, Miura, Daishu, Katagiri, Makoto, Nakashima, Noriaki, Ohishi, Hiroko, Shimazaki, Ryutaro, Tominaga, Yoshihiro

“…Pharmacological treatment of hypercalcemia is essential for patients with parathyroid carcinoma and intractable primary hyperparathyroidism (PHPT). Use of the…”
Get full text

Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study” by Akizawa, Tadao, Shimazaki, Ryutaro, Shiramoto, Masanari, Fukagawa, Masafumi

Get full text

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First.in.Human Phase I Study by Akizawa, Tadao, Shimazaki, Ryutaro, Shiramoto, Masanari, Fukagawa, Masafumi

“…Background and Objectives Evocalcet is a novel calcimimetic agent with potential to improve the treatment of secondary hyperparathyroidism in patients with…”
Get full text

Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses by Ishii, Hiroshi, Nomura, Takushi, Yamamoto, Hiroyuki, Nishizawa, Masako, Thu Hau, Trang Thi, Harada, Shigeyoshi, Seki, Sayuri, Nakamura-Hoshi, Midori, Okazaki, Midori, Daigen, Sachie, Kawana-Tachikawa, Ai, Nagata, Noriyo, Iwata-Yoshikawa, Naoko, Shiwa, Nozomi, Suzuki, Tadaki, Park, Eun-Sil, Ken, Maeda, Onodera, Taishi, Takahashi, Yoshimasa, Kusano, Kohji, Shimazaki, Ryutaro, Suzaki, Yuriko, Ami, Yasushi, Matano, Tetsuro

“…Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19) pandemic. Currently developed vaccines inducing severe acute…”
Get full text